BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Holdings Boosted by Teacher Retirement System of Texas

Teacher Retirement System of Texas grew its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 25.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 58,291 shares of the biotechnology company’s stock after purchasing an additional 11,711 shares during the quarter. Teacher Retirement System of Texas’ holdings in BioCryst Pharmaceuticals were worth $438,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in BCRX. The Manufacturers Life Insurance Company grew its stake in BioCryst Pharmaceuticals by 40.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock worth $2,274,000 after buying an additional 86,571 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after acquiring an additional 375,890 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock worth $14,890,000 after acquiring an additional 91,998 shares during the period. Geode Capital Management LLC lifted its position in BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after purchasing an additional 127,708 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in BioCryst Pharmaceuticals by 472.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company’s stock valued at $3,776,000 after purchasing an additional 409,938 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BCRX has been the topic of several analyst reports. JMP Securities restated a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Wedbush assumed coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an “outperform” rating and a $15.00 target price on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $11.00 price target (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Finally, Evercore ISI increased their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $15.57.

BioCryst Pharmaceuticals Trading Down 4.6 %

Shares of BioCryst Pharmaceuticals stock opened at $7.50 on Tuesday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $9.50. The stock has a market cap of $1.57 billion, a PE ratio of -12.29 and a beta of 1.85. The company’s 50-day moving average price is $8.18 and its two-hundred day moving average price is $7.82.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. BioCryst Pharmaceuticals’s quarterly revenue was up 40.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.28 EPS. On average, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.